TCIM
CDTX

TIAA CREF Investment Management’s Cidara Therapeutics CDTX Stock Holding History

TIAA CREF Investment Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,953
Closed -$305K – 3140
2017
Q1 		$305K Buy
1,953
+92
+5% +$16.2K ﹤0.01% 2923
2016
Q4 		$387K Buy
1,861
+72
+4% +$15K ﹤0.01% 2921
2016
Q3 		$410 Sell
1,789
-187
-9% -$43.2K ﹤0.01% 2932
2016
Q2 		$407K Buy
1,976
+1,207
+157% +$292K ﹤0.01% 2949
2016
Q1 		$195K Hold
769
– – ﹤0.01% 2979
2015
Q4 		$264K Sell
769
-254
-25% -$76.3K ﹤0.01% 3035
2015
Q3 		$260K Sell
1,023
-625
-38% -$179K ﹤0.01% 3014
2015
Q2 		$462K Buy
+1,648
New +$507K ﹤0.01% 2985

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TIAA CREF Investment Management's CDTX Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Cidara Therapeutics (CDTX) in Q2 2017, closing a stake of 1,953 shares — an estimated $305K sold.

TIAA CREF Investment Management first reported a position in CDTX in Q2 2015 and held it in 8 quarters. The position peaked at $462K in Q2 2015. 54 funds tracked by Wall St. Rank hold CDTX as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Cidara Therapeutics position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 1,953 Cidara Therapeutics shares in Q2 2017, an estimated $305K.
  • TIAA CREF Investment Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 8 quarters.
  • TIAA CREF Investment Management's Cidara Therapeutics position peaked at $462K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.